Frank Morich
Chairman bei CUE BIOPHARMA, INC.
Vermögen: 52 920 $ am 31.03.2024
Profil
Frank M.
Morich is currently the Chairman at Cue Biopharma, Inc. since 2020, the Executive Chairman at Aphaia Pharma AG since 2022, the Director at Viewpoint Molecular Targeting, Inc. since 2021, and the Director at Perspective Therapeutics, Inc. since 2023.
Previously, he served as the Chief Executive Officer & Director at Fujirebio Europe NV from 2005 to 2007, the Chief Executive Officer at NOXXON Pharma AG from 2008 to 2010, the President & Chief Executive Officer at Takeda A, the Deputy Chairman-Supervisory Board at MorphoSys AG from 2015 to 2020, the Chairman at Bayer HealthCare AG from 1982 to 2009, the Chairman-Executive Board & Chief Executive Officer at AM-Pharma BV, a Director at Bayer Corp., a Director at Bayer AG from 1982 to 2002, the Director & Chief Commercial Officer at Takeda Pharmaceutical Co., Ltd.
from 2012 to 2014, the Director-Clinical Research at Miles, Inc. from 1982 to 1991, a Director at Innate Pharma SA from 2004 to 2010, a Director at IsoRay, Inc., a Director at Viewpoint (US) from 2021 to 2023, and a Member-Supervisory Board at Neuro3D SA. He also served as the Executive Vice President-International Operations at Takeda Pharmaceuticals International, Inc. from 2011 to 2012 and as the Chief Commercial Officer at Takeda Pharmaceuticals International AG from 2011 to 2014.
Dr. Morich holds graduate and doctorate degrees from Philipps University of Marburg.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0,06% | 02.01.2024 | 28 000 ( 0,06% ) | 52 920 $ | 31.03.2024 |
| 22.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Frank Morich
| Unternehmen | Position | Beginn |
|---|---|---|
| CUE BIOPHARMA, INC. | Chairman | 01.04.2020 |
| PERSPECTIVE THERAPEUTICS, INC. | Director/Board Member | 03.02.2023 |
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Director/Board Member | 03.05.2021 |
Ehemalige bekannte Positionen von Frank Morich
| Unternehmen | Position | Ende |
|---|---|---|
| Viewpoint (US) | Director/Board Member | 03.02.2023 |
| MORPHOSYS AG | Director/Board Member | 27.05.2020 |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Corporate Officer/Principal | 01.01.2014 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Director/Board Member | 01.01.2014 |
| INNATE PHARMA | Director/Board Member | - |
Ausbildung von Frank Morich
| Philipps University of Marburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| BAYER AG | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| MORPHOSYS AG | Health Technology |
| INNATE PHARMA | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
Miles, Inc.
 Miles, Inc. Chemicals: Major DiversifiedProcess Industries Part of Bayer AG, Miles, Inc. is a chemical company. The private company is based in Pittsburgh, PA. | Process Industries |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |
Neuro3D SA
 Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
IsoRay, Inc.
 IsoRay, Inc. Medical SpecialtiesHealth Technology IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA. | Health Technology |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
Takeda Pharmaceuticals International AG
Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Health Technology |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Takeda Pharmaceuticals International, Inc.
 Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The private company is based in Deerfield, IL. | Commercial Services |
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Commercial Services |
| Viewpoint (US) | |
| Perspective Therapeutics, Inc. |
